Inovio Pharmaceuticals, Inc.

INO

NASDAQ

Healthcare

Biotechnology

Plymouth Meeting, PA, US134 employeesinovio.com

$1.13

-0.61(-35.06%)

Mkt Cap $61M

$1.13

$2.87

52-Week Range

At a Glance

AI-generated

Inovio Pharmaceuticals, Inc.

Revenue breakdown: Reportable Segments (100%).

8-K

Inovio Pharmaceuticals suspended its at-the-market equity offering program, halting future share sales until a new prospectus is filed, while the existing sales agreement remains in effect.

$61M

Market Cap

—

Revenue

-$10M

Net Income

Employees134

Fundamentals

How The Business Makes Money

Revenue by Segment

Reportable Segments100%($283.1K)

Activity

What Changed Recently

Financial Results

Mar 11, 2026

and Exhibit 99.1 hereto are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “

Material Agreement

Jan 26, 2026

Entry into a Material Definitive Agreement. On January 27, 2026, Inovio Pharmaceuticals, Inc. (the “Company”) amended each of its outstanding Series A warrants

Other Event

Apr 1, 2026

. | Other Events. | |---|---| On April 1, 2026 Inovio Pharmaceuticals, Inc. (the “Company”) notified Oppenheimer & Co. Inc. (the “Sales Agent”) that it was susp

Peer Companies

Company	Price	Change	Market Cap	P/E
IRDOpus Genetics, Inc.	$4.55	-2.99%	$324M	-57.6
ALECAlector, Inc.	$2.40	-5.14%	$265M	-1.5
ABOSAcumen Pharmaceuticals, I...	$2.70	+5.88%	$164M	-1.2
FATEFate Therapeutics, Inc.	$1.22	-1.61%	$142M	-1.0
SPROSpero Therapeutics, Inc.	$2.44	-0.61%	$141M	-3.0
AGENAgenus Inc.	$3.33	-1.91%	$128M	1133.3
SEERSeer, Inc.	$1.71	+0.29%	$96M	-1.3
MCRBSeres Therapeutics, Inc.	$9.25	+4.43%	$89M	13.5

Analyst View

Company Profile

CIK0001055726

ISINUS45773H4092

CUSIP45773H201

Phone267 440 4200

Address660 West Germantown Pike, Plymouth Meeting, PA, 19462, US

SEC EDGAR